On January 12, 2020 Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of next generation biologics using an expanded genetic code and Sino Biopharmaceutical Limited (1177.HK), a leading Chinese pharmaceutical company with a large number of medical products covering multiple therapeutic areas, reported a joint collaboration to develop two products enabled by Ambrx’s unique non-natural amino acid incorporation technology platforms (Press release, Ambrx, JAN 12, 2020, View Source [SID1234553077]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the agreement, Ambrx received an upfront payment to create two innovative drug candidates, with Sino Biopharma then leading IND enabling activities for both China and the US. The parties will jointly develop the programs to world-class standards with Sino Biopharma commercializing the products within the greater China area and Ambrx commercializing the products rest-of-world. Ambrx is eligible to receive additional milestone payments for development, regulatory, and sales-based events, as well as tiered royalties on future sales.
"We are delighted to join forces with Ambrx, a leader in precision engineered biologics and breakthrough protein therapeutics, to develop two next generation cancer drugs" commented Stephen Hsin Tse, Executive Director of Sino Biopharma. "This collaboration helps fulfill our strong commitment to develop and commercialize innovative biological drugs for the China market."
The collaboration combines Ambrx’s clinically validated ReCODE and EuCODE platforms with Sino Biopharma’s strong resources and commitment to bring nextgeneration biologic drugs to market.
"Sino Biopharma is a large, unique and fast-growing powerhouse in the Chinese pharmaceutical industry, combining strong drug development expertise with substantial commercial resources and infrastructure. We are delighted to collaborate with Sino Biopharma as we continue to push the boundaries of next generation biologics with our proprietary technologies." said Feng Tian, Ph.D., President and CEO of Ambrx. "We are very excited about the future of these two novel first-in-class and best-in-class drug candidates and look forward to working with Sino Biopharma to unleash the therapeutic potential of those drug candidates."